tirzepatide cause depression Can Depression? What to Watch For Retatrutide for weight loss: Study

March 2023.

Real-world safety data from the FDA Adverse Event Reporting System suggests that Mounjaro may actually have lower pancreatitis risk compared to some other GLP-1 receptor agonists: Mounjaro (tirzepatide): Adjusted ROR 2.74 (suggests the reporting rate is about 2.7 times higher than would be expected if there was no association) Liraglutide (Saxenda): ROR 4.76 (suggests the reporting rate is about 4.8 times higher than expected, making it higher risk than Mounjaro) Semaglutide (Wegovy/Ozempic): ROR 2.04 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) Dulaglutide (Trulicity): ROR 2.01 (suggests the reporting rate is about 2 times higher than expected, slightly lower than Mounjaro) While these numbers may seem complicated, they suggest that Mounjaros pancreatitis risk is comparable to or lower than that of other medications in the same class, with liraglutide showing a notably higher risk signal

Mounjaro is a dual GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes mellitus treatment

Jeff came to Formation from orthopaedics, which means hes done thousands of injections in technically demanding settings

Saniona / Nasdaq News (2023) 8

Labels, concentrations, sterility, storage, and handling can differ